U.S. National Institutes of Health (NIH)
-
A new study has highlighted one way insufficient sleep can harm your immune system, making you more vulnerable to infections and inflammatory disease by damaging your body’s hematopoietic stem cells.
-
Data from an annual drug-use survey has found use of psychedelics among US adults is at the highest point ever recorded in the survey’s history. The data also indicates alcohol and tobacco consumption is trending down but marijuana-use has increased.
-
A small autopsy study examining brain tissue from deceased COVID-19 patients is offering clues to how this coronavirus can lead to brain damage. The findings suggest an abnormal immune response could be damaging vascular cells in the blood-brain barrier.
-
Researchers at the National Institutes of Health are beginning a Phase 1 human trial to test a new universal flu vaccine. The trial will test the vaccine being delivered via nasal spray or by injection after animal studies demonstrated strong results.
-
Pneumonia is usually treated with antibiotics, but bacteria are developing resistance to them. Now, NIH researchers have found a way to boost immune cells to eat the bacteria more effectively, potentially leading to a new pneumonia treatment.
-
Johns Hopkins Medicine has been awarded a grant by the National Institutes of Health for research investigating psilocybin-assisted psychotherapy to treat tobacco addiction. The grant is the first federal funding in 50 years for psychedelic therapy.
-
Researchers on the hunt for a pre-approved medicine that can be repurposed to treat Alzheimer’s disease have found exposure to a common diuretic drug could significantly reduce a person’s risk of developing the disease.
-
The US National Institutes of Health is investing $470 million dollars into research on long COVID. The massive nationwide study into this often-debilitating condition will include tens of thousands of patients and span more than 30 research institutions.
-
The results of a major trial testing convalescent plasma therapy for COVID-19 in high-risk outpatients have been peer-reviewed and published. The once-promising therapy was found to be ineffective in preventing disease progression in high-risk patients.
-
When will COVID-19 vaccine booster shots be necessary? Pfizer claims a third booster of its vaccine may be needed six to 12 months after vaccination but not everyone is convinced, with new research finding mRNA vaccines may offer years of protection.
-
New studies from the NIH and the CDC have found SARS-CoV-2, the novel coronavirus responsible for COVID-19, was likely circulating around the United States for at least several weeks prior to the first officially reported case in late January 2020.
-
A clinical trial run by the NIH exploring the efficacy of convalescent plasma in treating mild to moderate COVID-19 patients has been halted. In a similar conclusion to prior trials, the once-promising treatment was deemed unlikely to be of any benefit.
Load More